Article Versions Notes

Crucitta S, Ruglioni M, Lorenzini G, Bargagna I, Luculli GI, Albanese I, Bilancio D, Patanè F, Fontana A, Danesi R, et al. CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients. Cancers. 2023; 15(4):1306. https://doi.org/10.3390/cancers15041306

Crucitta, Stefania, Martina Ruglioni, Giulia Lorenzini, Irene Bargagna, Giovanna Irene Luculli, Irene Albanese, Diana Bilancio, Francesca Patanè, Andrea Fontana, Romano Danesi, and et al. 2023. "CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients" Cancers 15, no. 4: 1306. https://doi.org/10.3390/cancers15041306

Crucitta, S., Ruglioni, M., Lorenzini, G., Bargagna, I., Luculli, G. I., Albanese, I., Bilancio, D., Patanè, F., Fontana, A., Danesi, R., & Del Re, M. (2023). CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients. Cancers, 15(4), 1306. https://doi.org/10.3390/cancers15041306